Genesis Research and Development announced this week that it has signed an agreement to sell roughly 7.4 million of its shares to an undisclosed investor in exchange for NZD$ 446,278 ($311,729).

The private placement, the New Zealand-based company said, is expected to close within the next two weeks.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

A federal grand jury has indicted Elizabeth Holmes and Ramesh Balwani for alleged wire fraud in conjunction with their activities at Theranos.

A direct-to-consumer genetic testing company sent out used spit kits, CNBC reports.

Nature News reports that some developers are nervous about GitHub's acquisition by Microsoft.

In PLOS this week: comparison of commercial bisulfite kits, new method to predict essential proteins, and more

Jul
19
Sponsored by
Thermo Fisher Scientific

This webinar will discuss how ultra-highly sensitive and customizable targeted next-generation sequencing panels are applied in inherited disease research.